Teva Canada Announces the Approval of TRUXIMA™\, the first biosimilar to RITUXAN® in Canada for the Treatment of Non-Hodgkin\'s Lymphoma\, Chronic Lymphocytic Leukemia and Rheumatoid Arthritis